FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.
The approval follows data from the phase 3 KEYNOTE-A18 trial, in which the drug with CRT demonstrated an improvement in progression-free survival (PFS), and reduced the risk of disease progression or death by 41% compared to placebo plus CRT.
This is the third approval for Keytruda in cervical cancer treatment and the 39th indication for the drug overall in the US.
[…]The post FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment appeared first on Pharmafile.
